@article{e116822e3f384ddf99def711dc766791,
title = "The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.",
author = "Mark Redell and Miguel Sierra-Hoffman and Maha Assi and Markian Bochan and David Chansolme and Anurag Gandhi and Kathleen Sheridan and Ivan Soosaipillai and Thomas Walsh and Jill Massey",
note = "In attempts to shorten or avoid hospitalization without increasing overall health care costs, 2 long-acting lipoglycopeptide molecules, oritavancin and dalbavancin, have been approved for use in acute bacterial skin and skin structure infections (ABSSSIs).",
year = "2019",
month = nov,
day = "1",
doi = "10.1093/OFID/OFZ479",
language = "American English",
volume = "6",
journal = "Open Forum Infectious Diseases",
number = "11",
}